The stock of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has decreased by -5.85 when compared to last closing price of 21.89.Despite this, the company has seen a loss of -16.76% in its stock price over the last five trading days. zacks.com reported 2024-10-01 that Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Is It Worth Investing in Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Right Now?
Moreover, the 36-month beta value for ARCT is 2.61. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARCT is 24.70M and currently, short sellers hold a 18.61% of that float. On October 11, 2024, ARCT’s average trading volume was 389.80K shares.
ARCT’s Market Performance
The stock of Arcturus Therapeutics Holdings Inc (ARCT) has seen a -16.76% decrease in the past week, with a -1.76% drop in the past month, and a -11.01% fall in the past quarter. The volatility ratio for the week is 6.00%, and the volatility levels for the past 30 days are at 6.09% for ARCT. The simple moving average for the past 20 days is -7.16% for ARCT’s stock, with a -28.43% simple moving average for the past 200 days.
Analysts’ Opinion of ARCT
Many brokerage firms have already submitted their reports for ARCT stocks, with Leerink Partners repeating the rating for ARCT by listing it as a “Outperform.” The predicted price for ARCT in the upcoming period, according to Leerink Partners is $70 based on the research report published on August 12, 2024 of the current year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see ARCT reach a price target of $90. The rating they have provided for ARCT stocks is “Buy” according to the report published on December 13th, 2023.
William Blair gave a rating of “Outperform” to ARCT, setting the target price at $71 in the report published on July 24th of the previous year.
ARCT Trading at -1.69% from the 50-Day Moving Average
After a stumble in the market that brought ARCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.20% of loss for the given period.
Volatility was left at 6.09%, however, over the last 30 days, the volatility rate increased by 6.00%, as shares surge +3.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.15% lower at present.
During the last 5 trading sessions, ARCT fell by -16.76%, which changed the moving average for the period of 200-days by -34.98% in comparison to the 20-day moving average, which settled at $22.20. In addition, Arcturus Therapeutics Holdings Inc saw -34.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARCT starting from SASSINE ANDY, who sale 50,000 shares at the price of $32.03 back on Jun 12 ’24. After this action, SASSINE ANDY now owns 220,526 shares of Arcturus Therapeutics Holdings Inc, valued at $1,601,500 using the latest closing price.
Chivukula Pad, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc, sale 114 shares at $45.00 during a trade that took place back on Jun 05 ’24, which means that Chivukula Pad is holding 447,334 shares at $5,130 based on the most recent closing price.
Stock Fundamentals for ARCT
Current profitability levels for the company are sitting at:
- -0.42 for the present operating margin
- 1.02 for the gross margin
The net margin for Arcturus Therapeutics Holdings Inc stands at -0.46. The total capital return value is set at -0.21. Equity return is now at value -25.32, with -16.80 for asset returns.
Based on Arcturus Therapeutics Holdings Inc (ARCT), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.21. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -2646.67.
Currently, EBITDA for the company is -1.2 million with net debt to EBITDA at 5.0. When we switch over and look at the enterprise to sales, we see a ratio of 1.82. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.78.
Conclusion
To wrap up, the performance of Arcturus Therapeutics Holdings Inc (ARCT) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
